KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Authors :: Jonathan D. Cheng
Ananya Roy
Wan Zamaniah Wan Ishak
Brett G.M. Hughes
Richard Greil
N. Baste Rotllan
Makoto Tahara
Tamara Rordorf
Ricard Mesia
T. Fuereder
Denis Soulières
Danny Rischin
Kevin J. Harrington
Nuttapong Ngamphaiboon
G. De Castro
Amanda Psyrri
Åse Bratland
Prakash Neupane
Fan Jin
Barbara Burtness
Source :: Annals of Oncology. 29:viii729
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
business.industry
First line
Hematology
Pembrolizumab
medicine.disease
Head and neck squamous-cell carcinoma
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Cancer research
Medicine
business

Full Text Access

Tools